The Worldwide Human Growth Hormone Drugs Industry is Projected to Reach $4 Billion by 2026 – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Human Growth Hormone Drugs - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

The global market for Human Growth Hormone Drugs estimated at US$3.3 Billion in the year 2020, is projected to reach a revised size of US$4 Billion by 2026, growing at a CAGR of 3.5% over the analysis period.

Subcutaneous, one of the segments analyzed in the report, is projected to grow at a 4% CAGR to reach US$2.7 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Intramuscular segment is readjusted to a revised 3.1% CAGR for the next 7-year period. This segment currently accounts for a 23.7% share of the global Human Growth Hormone Drugs market.

The U.S. Market is Estimated at $1.3 Billion in 2021, While China is Forecast to Reach $285.1 Million by 2026

The Human Growth Hormone Drugs market in the U.S. is estimated at US$1.3 Billion in the year 2021. The country currently accounts for a 40.12% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$285.1 Million in the year 2026 trailing a CAGR of 5.2% through the analysis period.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.5% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3% CAGR while Rest of European market (as defined in the study) will reach US$299.1 Million by the close of the analysis period.

Intravenous Segment to Reach $304.8 Million by 2026

In the global Intravenous segment, USA, Canada, Japan, China and Europe will drive the 2.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$231.8 Million in the year 2020 will reach a projected size of US$269.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$14.4 Million by the year 2026.

Select Competitors (Total 46 Featured) -

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/82csny

Go here to read the rest:

The Worldwide Human Growth Hormone Drugs Industry is Projected to Reach $4 Billion by 2026 - ResearchAndMarkets.com - Business Wire

Heartland Group Holdings’ (NZSE:HGH) earnings growth rate lags the 13% CAGR delivered to shareholders – Simply Wall St

Heartland Group Holdings Limited (NZSE:HGH) shareholders have seen the share price descend 14% over the month. But that doesn't change the fact that the returns over the last three years have been pleasing. After all, the share price is up a market-beating 19% in that time.

Although Heartland Group Holdings has shed NZ$95m from its market cap this week, let's take a look at its longer term fundamental trends and see if they've driven returns.

Check out our latest analysis for Heartland Group Holdings

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

During three years of share price growth, Heartland Group Holdings achieved compound earnings per share growth of 7.0% per year. We note that the 6% yearly (average) share price gain isn't too far from the EPS growth rate. Coincidence? Probably not. This suggests that sentiment and expectations have not changed drastically. Au contraire, the share price change has arguably mimicked the EPS growth.

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

We know that Heartland Group Holdings has improved its bottom line lately, but is it going to grow revenue? You could check out this free report showing analyst revenue forecasts.

When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. In the case of Heartland Group Holdings, it has a TSR of 44% for the last 3 years. That exceeds its share price return that we previously mentioned. The dividends paid by the company have thusly boosted the total shareholder return.

It's nice to see that Heartland Group Holdings shareholders have received a total shareholder return of 4.0% over the last year. And that does include the dividend. However, that falls short of the 9% TSR per annum it has made for shareholders, each year, over five years. The pessimistic view would be that be that the stock has its best days behind it, but on the other hand the price might simply be moderating while the business itself continues to execute. It's always interesting to track share price performance over the longer term. But to understand Heartland Group Holdings better, we need to consider many other factors. For instance, we've identified 3 warning signs for Heartland Group Holdings (1 is potentially serious) that you should be aware of.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on NZ exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Originally posted here:

Heartland Group Holdings' (NZSE:HGH) earnings growth rate lags the 13% CAGR delivered to shareholders - Simply Wall St

Never Take This After Age 50, Warn Pharmacists Eat This Not That – Eat This, Not That

Nutrition is crucial for healthy aging, but supplements are not as effective as food when it comes to getting the right amounts of vitamins and mineralsand some can actually be dangerous. "My motto is always 'food first,'" says Rachel Berman, R.D., Director of Nutrition for Calorie Count. "Foods found in nature are always more nutritious because our bodies are used to processing vitamins and minerals that come from natural sources." Here are five supplements you should never take after 50. Read onand to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID.

A study from UC Davis showed that too much folic acid can aggravate complications related to vitamin B-12 deficiency, which could result in dangerous health conditions such as anemia and neurological damage. "There have been concerns that some people may be getting too much folic acid through a combination of sources, and we wanted to determine if there were reasons for those concerns," says Ralph Green, UC Davis professor of pathology and laboratory medicine. "Our results show that higher levels of folic acid could set in motion a metabolic imbalance that leads to more serious B-12 deficiency We do have to worry about folic-acid supplementation. The fact is that a lot of people are getting more of it than is good for them. If they happen to be B-12 deficient, more folic acid may actually harm them."

6254a4d1642c605c54bf1cab17d50f1e

Hormone therapy such as HGH (human growth hormone) can be dangerous, experts warn. "In this entire field, I've only encountered one board-certified endocrinologist," says Thomas Perls, M.D., associate professor of medicine and geriatrics at Boston University School of Medicine. "It's outrageous that people think they can prescribe these toxic hormone soups There is no scientific proof of this. And studies show that increasing HGH levels with drugs predisposes people to heart disease, diabetes, and cancer."

Anti-aging supplements have not been proven to work, experts warn, and most are not regulated by the FDA. "Many anti-aging doctors sell their own lines of nutraceuticals at very high prices," says Dr. Perls. "It's a profit margin that's better than what cocaine dealers get."

"We don't know if they could help, but they could be harmful," says Winifred K. Rossi, deputy director of the Division of Geriatrics and Gerontology at the National Institute on Aging.

Vitamin E is a common ingredient in brain health supplements, but too much can be dangerous.

"High doses of vitamin E supplements are associated with an increased risk of death," says dietitian Maxine Smith, RDN, LD, who recommends getting vitamin E from foods such as nuts, seeds, and dark green leafy vegetables.

Over-the-counter sexual enhancement products should be avoided, experts warn. "Products promising to enhance sexual performance have been promoted for over a century, dating back to the patent medicines of the 1800s; these products were characterized by wildly exaggerated claims and sold to the public by unscrupulous manufacturers, without evidence of safety or effectiveness," says W. Steven Pray, PhD, DPh. "Some manufacturers of impotence cures claim that their product is 'scientifically proven' to work. When a consumer sees the phrase 'clinical studies prove it works,' caution is in order, as these claims are often false. Furthermore, claims providing very high rates of success are often bogus." And to protect your life and the lives of others, don't visit any of these 35 Places You're Most Likely to Catch COVID.

Ferozan Mast

More here:

Never Take This After Age 50, Warn Pharmacists Eat This Not That - Eat This, Not That

Sleeping Tips for Runners and Why Rest Is So Important – runnersworld.com

Theres no doubt that sleep does the body goodits essential to reach the best state of physical and mental health. But oftentimes, we sacrifice sleep to fit in the demands of our everyday livesfamily, work, training, the list goes on.

While it may seem like you can make withdrawals from your sleep bank account without issue, your sleep debt (or not getting enough sleep over multiple days, as defined by the CDC) can build up over time and make it difficult for you to catch up on zzzs, leaving you feeling tired all. the. time.

So to help you catch more shut-eye, we spoke with experts to break down exactly why you need so much sleep, what it does for your performance, and how to get more quality rest.

As a runner, you probably know how important recovery is to your training (at least you should!). And your body does its best form of recovery and regeneration during your sleep cycles. Catching that shut-eye creates an optimal environment for your body to repair your muscle cells, which is what then leads to improved physical fitness over time.

A solid seven to nine hours of sleep will give your body the time it needs to go through the phases of recovery and can help prevent injury. When your body gets the sleep it needs, your immune system is also better equipped to stave off sickness. On the other hand, if you chronically miss out on rest, it can increase inflammation in the body, which can increase risk of disease, according to research.

Your eating habits can also be related to your sleep. While the research on sleep deprivation versus appetite is skewed, there is evidence that sleep is linked to your appetite hormones. These are known as leptin and ghrelin. People that have poor sleep, or not enough sleep, those appetite hormones are altered in a way that can affect metabolism and weight gain, says Ryan Soose, M.D., director of the sleep division and associate professor in the department of otolaryngology at the University of Pittsburgh.

Research also shows a link between good sleep quality and better mental health.

Soose says sleep is important for restoration and repair of nerves, muscles, and other tissues. Sleep, especially deep sleep, is when growth hormone is released, which is important for athletic training, he says. Human growth hormone (or HGH) is responsible for cell regeneration within tissues and organs all over the body. It also influences your basal metabolic function, including uptake of amino acids and protein synthesis.

Theres plenty of evidence now that chronic sleep deprivation, and reduced quality or quantity of sleep, is associated with increased injury rate, increased reports of chronic pain issues, reduced endurance, and even reduced cognition, Soose says.

Different stages of sleep bring on different types of recovery. Scott Kutscher, M.D., clinical associate professor of psychiatry and behavioral sciences at Stanford Sleep Medicine Center explains what happens during the sleep phases and why hitting them (which is what makes your sleep quality rest) is so important for runners:

You usually go through multiple sleep cycles (between four to six) while youre asleep, moving between light sleep, deeper sleep, deepest (or slow-wave) sleep, and REM sleep, with most shut-eye (about 75%) occurring in the non-REM sleep stage.

Slow wave sleep is important for physical recovery, and REM sleep is important for mental recovery, Kutscher says. In slow wave sleep, our bodys metabolism is at its lowest rate, our heart rate and blood pressure are at their lowest rates. REM sleep is typically when we consolidate our memories. This is important for racing too because running is also a mental phenomenon. You need the focus and the reaction time.

REM sleep is typically responsible for your dreams and youre usually more restless during this stage, with possible irregular muscle movements. If youre running longer races, that requires constant attention to your tasks, whether its monitoring your pace, your breath rate, thinking about your form, or mentally pushing through tough intervals. These are the areas that you can lag if youre skipping on REM sleep.

If youre getting up early for a morning run or workout, combined with not getting a full night of rest, youre potentially losing out on slow-wave sleep.

Slow wave sleep is usually referred to as the deepest sleep stage. Its when your brain waves are the slowest, and its harder to be woken up from this stage. Your growth hormone secretion is at its greatest level during this stage, too. Its the time during your sleep cycle when your body gets to work restoring and regrowing tissues, building bone and muscle and strengthening the immune system. If youre missing out on this important stage, your body will have a harder time recovering after a challenging workout or run.

Because your body is working extra hard during training, skipping out on necessary sleep stages will become even more noticeable. Even a day or two of less than seven hours of sleep can decrease reaction times significantly, Kutscher says. Your reaction time is how quickly you respond to stimulus. Whether you run sprints or like to run trails, your reaction time will improve your performance and help prevent injury and accidents.

A study published in Physiology & Behavior in 2020 suggests that just one night of sleep deprivation can affect your performance the next day. Researchers tested a group of 20 runners after they got varying amounts of sleep and had them perform two 12-minute exercises. Researchers ran one test after a night of six and a half hours of sleep, the other after a night of partial sleep (ranging from a half hour to four and a half hours).

They found that after the night of less rest, runners exhibited a higher rate of exertion, lower physical performance, and a change of heart ratenot to mention, a difference in overall mood.

As mentioned, skimping on sleep can also impair your recovery, which can make subsequent runs more difficult. It can also tank your mood and concentration, making your mental game suffer on the run.

Not only is the amount of sleep you get important for performance, but so is the quality of sleep you getand that means hitting all stages. If youre going to bed and waking up at random times, or if you cant seem to settle once your head hits the pillow, here are some tips to help you out:

Go to bed and get up at the same time every day. Make sure [those bed times and wake-up times are] giving you an adequate amount of sleep, and stick to them, Kutscher says. This sets your bodys circadian rhythm, helping you feel more tired around bedtime and more awake in the morning.

Avoid heavy meals before you hit the hay, and skip the caffeine and alcohol. They can cause stimulating effects, which make it harder to fall asleep, and they can mess with your sleep quality.

One study published in Sleep Medicine Reviews in 2021 also shows that there may be a link between diet and sleep quality. Consumption of healthy foods (think fruits and veggies) helps to promote better sleep, while high intake of processed foods and sugar-rich items may trigger sleep problems.

A study published in Mindfulness in 2021 suggests that mind-body activities, like practicing mindfulness, might improve sleep quality over time in people with chronic pain. Consider incorporating mindful exercises like meditation, yoga, or breathing techniques into your daily routine to boost relaxation and help you catch more shut-eye.

Soose recommends creating a space that is cool, comfortable, and dark. Athletes are often in hotels and different environments that physically make it hard to get the right amount of sleep. The more you can control that bedroom or sleep environment, the better, he says.

Just being a runner should pay off in better sleep, as exercise can improve your rest. Research shows physical activity, particularly weight training, promotes better sleep habits. Exercising earlier in the day may help you fall asleep easier at night.

Winding down before bed, sans your devices, can positively influence your sleep hygiene. Thats because the light on your phone, TV, or tablet can mimic sunlight and then mess with your sleep-wake cycle, according to research. Try to ditch screens 30 to 60 minutes before hitting the pillow.

It can be challenging to switch up your sleep schedule and get into a healthier routinesome habits may be easier to kick than others. One of the important factors is follow-through: If youre noticing more lethargy during your runs or your body isnt recovering as fast after a few hard workouts, your sleep routine may be the culprit. Start with one small change, like going to bed 20 minutes earlier, and take it from there.

Lastly, if you find that your sleep difficulties dont improve after testing out new practices, consult your physician or a specialist. Sleep disorders like apnea and restless legs syndrome could be at play. A professional can help you create a plan for quality sleep so that youre well-rested and ready to hit the ground running.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

See the article here:

Sleeping Tips for Runners and Why Rest Is So Important - runnersworld.com

This Week in Local History June 15, 2022 The Review Archives 1972: WWF stars injured in highway crash 1922: Mystery of disappearing bridegroom…

10 Years agoZellers closes to make way for WalmartThe Review, June 13, 2012 HAWKESBURY Although the community knew it was going to happen, it was still a bit of a shock to watch as the familiar Zellers sign was removed from the stores long-time location on Cameron Street on June 7. After weeks of sales advertising that everything must go, the store is finally resigning to its fate to be turned into a Walmart.

25 Years AgoFour WWF stars treated at HGH after highway crashThe Review, June 18, 1997 HAWKESBURY Four celebrity wrestlers from the World Wresting Federation were treated at Hawkesbury General Hospital, after being hurt on Sunday in a single-car accident near Pointe Fortune on Highway 40. The wrestlers Sydney Psycho Sid Eudy, Charles Flash Funk Scaggs, Philip Lafon, and Dwight Furnas were in a Lincoln Continental that was heading from Montreal to Ottawa when the driver lost control of the car while adjusting the sunroof. Furnas suffered the most serious injury, with an apparent broken shoulder blade.

50 Years AgoTwo killed in head-on Highway 34 crashThe Review, June 14, 1972 VANKLEEK HILL Two Vankleek Hill residents died in a head on collision on Highway 34 about two kilometres north of Vankleek Hill. Rejean Morin, 33, and Dolores Sauve were in a 1965 Pontiac that collided with a 1965 Chevrolet containing three people. Yvon and Lise Lalonde and Danielle Filion, occupants of the second car were seriously injured in the accident.

75 Years AgoRecord cattle entries for Lachute FairThe Review, June 12, 1947 LACHUTE The Lachute Spring Fair this week promises to be an outstanding event. Dairy cattle entries have broken previous records, with 191 head of Ayrshires, 125 Holsteins, 20 Canadian and 25 head of Dairy Shorthorns. In sheep, there are 207 head entered and 100 swine. There are 165 heavy horses and well over 100 light horses. A catalogue listing the entries will be available at the commencement of the fair.

100 Years AgoMystery of disappearing bridegroom solvedThe Review, June 16, 1922 GLEN SANDFIELD The mystery of what happened to John McKinnon, a young and well-to-do farmer who disappeared nine weeks ago the day before he was to be married has been solved. In a letter to his friend Harry Gordon, McKinnon gave a detailed explanation of the real cause of his sudden disappearance. The letter, which is dated in the Nipissing District, is now in the hands of the authorities, In Glen Sandfield, the girl he was to have wed sits weeping and waiting for him to come home, however McKinnon states in the letter that he will not be returning.

125 Years AgoDiphtheria health resolutions must be enforcedThe Review, June 18, 1897 VANKLEEK HILL It is to be hoped that the resolutions adopted at the meeting of the Board of Health on Wednesday will be rigidly enforced. Simply placing a placard on the door of a house in which there is diphtheria is not a sufficient safeguard, especially if the door of the house on which the placard is placed is kept open and the placard obscured. The Board of Health is our health protector and we expect and demand protection its power is unlimited.

Read the original here:

This Week in Local History June 15, 2022 The Review Archives 1972: WWF stars injured in highway crash 1922: Mystery of disappearing bridegroom...

Recombinant Bovine Growth Hormone – American Cancer Society

Recombinant bovine growth hormone (rBGH) is a synthetic (man-made) hormone that is marketed to dairy farmers to increase milk production in cows. It has been used in the United States since it was approved by the Food and Drug Administration (FDA) in 1993, but its use is not permitted in the European Union, Canada, and some other countries. This document summarizes what is known about the product and its potential effects on health.

The human form of growth hormone, also calledsomatotropin, is made by the pituitary gland. It promotes growth and cell replication. Bovine growth hormone (BGH), also known asbovinesomatotropin(BST) is the natural form of this hormone in cattle.

Recombinant bovine growth hormone (rBGH) or recombinant bovine somatotropin (rBST) refers to bovine growth hormone that is made in a lab using genetic technology. Some rBGH products on the market differ chemically from a cow's natural somatotropin by one amino acid. Both the natural and recombinant forms of the hormone stimulate a cow's milk production by increasing levels of another hormone known as insulin-like growth factor (IGF-1).

Concerns about possible health effects on humans from milk produced using rBGH have focused on 2 main issues.

First, does drinking milk from rBGH-treated cows increase blood levels of growth hormone or IGF-1 in consumers? If it does, would this be expected to have any health effects in people, including increasing the risk of cancer? Several scientific reviews have looked at these issues and are the main focus of this document.

Second, cows treated with rBGH tend to develop more udder infections (mastitis). These cows are given more antibiotics than cows not given rBGH. Does this increased use of antibiotics lead to more antibiotic-resistant bacteria, and is this a health concern for people? This remains a concern, but it has not been fully examined in humans.

Bovine growth hormone levels are not significantly higher in milk from rBGH-treated cows. On top of this, BGH is not active in humans, so even if it were absorbed from drinking milk, it wouldn't be expected to cause health effects.

Of greater concern is the fact that milk from rBGH-treated cows has higher levels of IGF-1, a hormone that normally helps some types of cells to grow. Several studies have found that IGF-1 levels at the high end of the normal range may influence the development of certain tumors. Some early studies found a relationship between blood levels of IGF-1 and the development ofprostate,breast,colorectal, and other cancers, but later studies have failed to confirm these reports or have found weaker relationships. While there may be a link between IGF-1 blood levels and cancer, the exact nature of this link remains unclear.

Some studies have shown that adults who drink milk have about 10% higher levels of IGF-1 in their blood than those who drink little or no milk. But this same finding has also been reported in people who drink soy milk. This suggests that the increase in IGF-1 may not be specific to cow's milk, and may be caused by protein, minerals, or some other factors in milk unrelated to rBGH. There have been no direct comparisons of IGF-1 levels in people who drink ordinary cow's milk vs. milk stimulated by rBGH.

At this time, it is not clear that drinking milk, produced with or without rBGH treatment, increases blood IGF-1 levels into a range that might be of concern regarding cancer risk or other health effects.

In the early 1990s, the FDA and other organizations looked at 3 questions regarding IGF-1 exposure from rBGH-treated milk. These were:

The available evidence can be summarized as follows:

At least 8 other national and international review committees have evaluated the evidence concerning potential health effects of rBGH on humans and dairy cows. These reviews (and the most recent year they convened) are listed below. Several of these reports document adverse effects on cows, including higher rates of mastitis, foot problems, and injection site reactions.

Although the use of rBGH is still approved in the United States, demand for the product has decreased in recent years. Many large grocery store chains no longer carry milk from cows treated with rBGH. A United States Department of Agriculture survey conducted in 2007 found that less than 1 in 5 cows (17%) were being injected with rBGH.

The available evidence shows that the use of rBGH can cause adverse health effects in cows. The evidence for potential harm to humans is inconclusive. It is not clear that drinking milk produced using rBGH significantly increases IGF-1 levels in humans or adds to the risk of developing cancer. More research is needed to help better address these concerns.

The increased use of antibiotics to treat rBGH-induced mastitis does promote the development of antibiotic-resistant bacteria, but the extent to which these are transmitted to humans is unclear.

The American Cancer Society (ACS) has no formal position regarding rBGH.

Go here to see the original:

Recombinant Bovine Growth Hormone - American Cancer Society

Official GenF20 Plus | Best Human Growth Hormone Releaser

The Enteric Absorption System contains 16 powerful ingredients, each playing an important role in stimulating your body to naturally increase your HGH levels, including:

Clinical studies have shown the arginine canas much as triple your HGH levels, even into old age. And it can also help improve your exercise performance for high-intensity, short duration work outs.

It increases fat burning, builds muscle tissue, boosts immunity, fights cancer, promotes healing, enhances male fertility, and more!

Your body doesnt naturally produce arginine; you must get it from your diet. So its an important addition to GenF20 Plus!

Its the amino acid used most by your body during times of stress, and its the key to metabolism andmaintenance of muscle, cell division, and cell growth. It increases energy and mental alertness.

Plus studies have shown that it boosts immunity, lowers cholesterol, lowers blood pressure, mitigates risk factors of arthritis, diabetes, heart disease, and more!

Its one of the key stimulatory agents thatencourages the pituitary gland to secrete HGH!It also has a calming effect on the brain and may play a role in the health of the prostate.

When lysine is taken in combination with arginine,its been shown to be ten times more effective than just taking arginine alone.It too is reported to boost immunity and improve genital function!

Tyrosine is used by the thyroid gland for the production of Thyroxine, another vital hormone shown in clinical studies to help reduce fatigue and depression, as well as regulate growth and metabolism!

In western herbal medicine, Astragalus is often used to enhance metabolism and digestion,strengthen the immune system and help wounds and injuries heal.It is also believed to help improve the function of the lung, adrenal glands and the gastrointestinal tract, increase metabolism, sweating, and reduce fatigue.

Deer antler velvet is a natural source of glucosamine, chondroitin and collagen. The body uses glucosamine to manufacture glycosaminoglycans that are found in cartilage tissue.

Deer antler velvet also contains male and female hormones, including Insulin-like growth factor I (IGF-1) a hormone thats produced in the liver as a response togrowth hormone stimulation,IGF-1 (somatomedin C).

GABA, or Gamma-Aminobutryic Acid, is a powerful amino acid that was first discovered in 1883 in Berlin. It is classified as a neurotransmitter, which means it helps nerve impulses cross the synapses (gaps) and communicate better and has a number of positive effects on the nervous system.In addition, GABA stimulates the production of Human Growth Hormone (HGH).

Benefits include increased immunity, accelerated healing, increased bone and lean and muscle mass, and mitigation of aging factors!

Colostrum contains IGF-1 (insulin like growth factors), which are actually products of HGH. IGF-1 is used to measure HGH production levels and its thought that IGF-1 is actuallyresponsible for the anti-aging effects of HGH.

Colostrum is a form of milk produced by the mammary glands of mammals in late pregnancy and the few days after giving birth. GenF20 Plus includes Bovine Colostrum, which is virtually identical to human colostrum and actually contains MORE of some of the most beneficial properties!

L-Valine is an amino acid and a branched-chain amino acid found in high concentration in the muscles. L-Valine cannot be made by the body, and must be acquired through food or dietary supplements. It has a stimulating effect and is needed for muscle metabolism, repair and growth of tissue and maintaining the nitrogen balance in the body. Since it is a branched-chain amino acid, it can be used as an energy source in the muscles, and in doing so preserves the use of glucose.

Itstimulates the pituitary gland to operate more effectivelyand increase the release of HGH. As well, its believed to help improve some conditions associated with aging, including poor muscle tone.

Its a purified extract from lecithin which acts as an excellent emulsifier, facilitating the absorption of the other nutrients included in GenF20 Plus.

Phosphatidyl Choline also emulsifies and breaks down fat deposits in the body, making it helpful in the mitigation of risk factors for gallstones, atherosclerosis, heart disease, and liver problems, depression, memory loss, and neurological disorders.

Studies have shown that Ornithine is about doubly effective as arginine, which as mentioned above, can as much astriple your HGH levels!Especially when used in combination with arginine, lysine, and glutamine, also included in GenF20 Plus

Required to transport glucose from the blood into the cells, chromium helps maintain glucose levels by enhancing insulin activity. And lower blood glucose levels canincrease the release of HGH!

Chromium also assists with weight control, helping you to maintain a healthy metabolism, increasing your energy, and reducing body fat!

Originally posted here:

Official GenF20 Plus | Best Human Growth Hormone Releaser

Top 10 Reasons Why You Need to Deadlift | BOXROX – BOXROX

There are many reasons why you need to deadlift. This simple exercise activates some of the largest muscle groups in your body and is perfectly transferrable to day-to-day life.

The Deadlift is a full body compound barbell exercise that involves lifting the weight from the floor to the standing position with the arms straight down by the sides or the body.

A good deadlift will help you build midline stability and teach you how to safely pick up objects from the floor.

Before we delve into the benefits of this fantastic exercise, learn how to perform a proper deadlift:

Read more: How to Deadlift

Strength training is known for being able to improve your mood, state of mind, and increase your confidence. As you increase your strength and lift heavier, this will only increase.

Deadlifts will strengthen your midline, which in return will improve your posture and give you core stability and strength.

Especially if you spend the majority of you day sitting down, deadlifts can help minimise the negative effects this can have on your posture.

One of the reasons why you need to deadlift is because the exercise isnt a highly-technical movement, which means anyone can do them. Young, old, trained, or a newbie, deadlifts are a great strength training exercise.

Improving your deadlift will translate to stronger lifts elsewhere. Whether its bench pressing, squatting, bent over rows, or anything in between will benefit from you doing more deadlifts.

You dont always have to chase the heaviest number, performing 8+ reps of deadlifts can help improve your cardiovascular health and induce more fat burn.

Deadlifting is one of the most functional strength exercises. This means, it has real life lifting applications and, as such, can help prevent injury.

If you deadlift you know how to pick heavy things up and build the strength required to do so.

This exercise will not only increase your grip strength but also your overall strength, which is a great reason why you need to deadlift more. As a compound movement, it works many of the biggest muscles in your body and can be used as a measure of overall strength.

If you perform deadlifts with good form, follow the right technique, and do them at a weight you are comfortable with, they are a safe exercise. They are very easy to bail out of as well when you feel your form deteriorating.

Deadlifts increase hormone production, which means more testosterone and growth hormone. This, in turn, means more muscle and strength.

Read more: How to Increase Testosterone Naturally

Deadlifts work nearly all the major muscle groups in your body, so instead of performing countless isolation exercises, you can work many muscles at once with the deadlift.

Excerpt from:

Top 10 Reasons Why You Need to Deadlift | BOXROX - BOXROX

New Phase 1b/2 Clinical Research Study with SynDevRx Drug Evexomostat (SDX-7320) Announced for Triple-Negative Breast Cancer Patients with Baseline…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--SynDevRx, Inc. today announced the opening of a first-of-its-kind Phase 1b/2 study for patients with triple-negative breast cancer and baseline insulin resistance, testing the novel study drug evexomostat (SDX-7320) in combination with standard-of-care treatment Halaven (eribulin, Esai). Evexomostat is among the first anti-cancer therapeutics being developed specifically for cancer patients with baseline metabolic dysfunction (obesity, type 2 diabetes and pre-diabetes). The clinical research study is being conducted in collaboration with New Yorks Memorial Sloan Kettering Cancer Center (MSK).

Insulin resistance, also known as hyperinsulinemia, is a condition that can go undetected until a patient develops overt type two diabetes mellitus (T2D) or elevated HbA1c. Insulin controls blood glucose levels but is also a potent growth hormone. It has been widely reported that high insulin levels in the presence of certain cancers, like breast cancer1, can cause the tumors to grow faster, become more difficult to treat and lead to premature cancer progression with worse patient outcomes2. The aim of this research study is to explore the impact of targeting insulin and improving insulin resistance in combination with standard-of-care therapy on patients treatment response and outcomes. It is the first prospective study using a clinical therapeutic designed specifically to address this critical, yet grossly understudied aspect of cancer progression.

Dr. Neil Iyengar, MD, an MSK breast medical oncologist and principal investigator of this study, has been at the forefront of researching the negative influences that dysregulated metabolic hormones, like insulin, play in cancer patients treatment outcomes.

Metabolic hormones play an important role in cancer establishment and progression, and are likely deterministic to patients clinical outcomes, Dr. Iyengar said. The area of metabo-oncology research, historically overlooked, has gained momentum over the past several years, and may soon emerge as an essential aspect of cancer treatment. It is known that a patients metabolic health status impacts survival after cancer diagnosis, and in some cases, how well and for how long cancer treatment is effective.

In a previous study, evexomostat (SDX-7320) demonstrated potent effects on elevated insulin levels in late-stage cancer patients, while preventing new metastases in several patients and with an acceptable safety profile, said Bradley Carver, co-founder and Chief Executive Officer of SynDevRx. While the focus of this clinical study is targeting insulin levels and the impacts on TNBC progression, the additional anti-angiogenic effects of evexomostat (SDX-7320) also seen in a phase 1 study may independently enhance clinical benefits for patients. Further, oncologists typically dont consider their patients metabolic health when designing treatment regimens. This study could change that. Dr. Iyengars trailblazing research and deep understanding of the metabo-oncology patient population, along with MSKs exceptional reputation for outstanding and innovative research is the perfect opportunity to showcase the multi-faceted effects of evexomostat (SDX-7320) for breast cancer patients, said Bradley Carver.

SynDevRx is at the forefront of metabo-oncology research and drug development, and we appreciate all the efforts from the team at MSK to bring this new experimental treatment paradigm to patients, Carver continued. Dr. Iyengars unique experience integrating patients metabolic health with their cancer treatment has resulted in a study design that we believe could lead to future clinical practices that incorporate patients insulin levels and overall metabolic health into their cancer treatment regimens.

SynDevRx is establishing global collaborations with leading research institutions focused on the downstream effects that obesity and dysregulated metabolic hormones have on cancer progression and metastasis. We invite other researchers to work with us as we untangle these complex and critical interactions between cancer and dysregulated metabolic hormones, said SynDevRxs co-founder and Chief Business Officer James Shanahan.

About Evexomostat (SDX-7320)

Evexomostat (SDX-7320) is among the first drugs being developed specifically for cancer patients with metabolic complications, such as obesity, diabetes, high blood glucose or HbA1c, pre-diabetes or insulin/leptin resistance. For certain tumor types, metabolic hormones stimulate oncogenic pathways, making the cancer more aggressive and deadlier. Evexomostat acts by binding irreversibly to its target enzyme MetAP2, triggering downstream improvements in the metabolic hormones insulin, leptin and adiponectin, regulation of key lipids, and inhibition of the important angiogenic proteins bFGF and VEGF-C, as was demonstrated in a Phase 1 clinical study in late-stage cancer patients. In preclinical studies, evexomostat also directly inhibited multiple cell cycle signaling pathways, provided synergistic anti-tumor effects in combination with a PI3K inhibitor, reduced angiogenesis, controlled aberrant metabolic hormone signaling, and reversed obesity-induced immune suppression within the tumor micro-environment of tumor-bearing obese mice. Evexomostat is being developed for use in combination with clinically indicated standard-of-care cancer therapies for breast and other tumor types.

About SynDevRx, Inc.

SynDevRx is a privately held clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. that is leading the research and development of treatments that address the interactions between cancer and dysregulated metabolic hormones. i.e., metabo-oncology. Obesity, pre-diabetes and type 2 diabetes are known to worsen certain cancer patients prognoses, but oncologists have no specific tools to treat systemic or treatment-induced metabolic complications, except for diet and exercise. SynDevRx is initiating a series of proof-of-concept clinical studies of its drug candidate evexomostat (SDX-7320) to show that improving these hormones together with effects on angiogenesis and the tumor micro-environment will result in better patient outcomes, thereby establishing a new and complementary treatment paradigm for tens of thousands of cancer patients. For more information visit http://www.syndevrx.com.

See the original post here:

New Phase 1b/2 Clinical Research Study with SynDevRx Drug Evexomostat (SDX-7320) Announced for Triple-Negative Breast Cancer Patients with Baseline...

North America Biosimilars Market is projected to grow at CAGR of 25.1% by 2030 The Greater Binghamton Business Journal – The Greater Binghamton…

North America Biosimilars Market report listed by Bonafide Research delivers a complete overview of key components like drivers, limitations, historic and current trends, technical development, and future growth. Research report contains company analysis, size, share, revenue and sales of the company, current advancements. North America Biosimilars Market analysis also focuses on the global key top industry players in the market, with details such as company profiles, capacity, production, price, cost, revenue.

North America biosimilars market is expected to grow by 25.1% annually in the forecast period and reach $27.57 billion by 2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.

Get a free sample report : https://www.bonafideresearch.com/samplereport/92001175/north-america-biosimilars-market

Highlighted with 29 tables and 54 figures, this 116-page report North America Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire North America biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).

In-depth qualitative analyses include identification and investigation of the following aspects: Market Structure Growth Drivers Restraints and Challenges Emerging Product Trends & Market Opportunities Porters Fiver Forces

The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Country.

Based on Product Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. Recombinant Non-glycosylated Biosimilars Insulin Recombinant Human Growth Hormone (rHGH) Granulocyte Colony Stimulating Factor Interferon Recombinant Glycosylated Biosimilars Monoclonal Antibodies (mAb) Erythropoietin (EPO) Follicle Stimulating Hormone Recombinant Peptides and Others Tumor Necrosis Factor (TNF)-Inhibitor Parathyroid Hormone Enzymes, Immunomodulators, GnRH Analogs and Others

Based on Indication, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. Cancer Autoimmune Disease Blood Disorder Diabetes Growth Hormone Deficiency Infectious Diseases Other Indications

Based on Manufacturing, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. Contract Manufacturing Inhouse Manufacturing

Based on End User, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. Hospitals and Clinics Research Institutes Other End Users

Geographically, the following national/local markets are fully investigated: U.S. Canada MexicoFor each key country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of key national markets by Product Type, Indication, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.Key Players (this may not be a complete list and extra companies can be added upon request):AMEGA Biotech S.A.Apotex Inc.Biocon LtdBiogen Inc.Boehringer IngelheimCelltrion, Inc.Dr. Reddys Laboratories Ltd.Eli Lilly and CompanyIntas Pharmaceuticals Ltd.LG Chem, Ltd.Merck and Co. Inc.Mylan N.V.Pfizer Inc.Samsung Biologics Co., Ltd.Sandoz International GmbHSTADA Arzneimittel AGTeva Pharmaceutical Industries Ltd.(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Key Indicators Analysed Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2020-2030 & Sales with a thorough analysis of the markets competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors. Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2020-2030 . Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications. Market Trends: Market key trends which include Increased Competition and Continuous Innovations. Opportunities and Drivers: Identifying the Growing Demands and New Technology Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Get full access of the report : https://www.bonafideresearch.com/product/92001175/north-america-biosimilars-market

CONTACT US:

Steven Thomas Sales & Marketing ManagerE-mail: sales@bonafideresearch.comAsia-Pacific: +91 7878231309Europe: +44 20 8089 0049North America: +1 201 793 8545https://www.bonafideresearch.com/

ABOUT US:

Bonafide Research is the fastest growing global market research and consulting company providing syndicated research reports, customized research reports, and consulting services to a range of verticals. They have been closely working with a wide client base ranging from Fortune 1000 companies to small and medium enterprises by helping them in tracking the constantly changing market scenario.

Bonafide has continuously made efforts to evolve and enhance the report quality with each passing day. Bonafide Research has a strong base of analysts and consultants from assorted areas of expertise who track the latest economic, demographic, trade and market data globally and help clients to make informed business decisions. They periodically update their market research studies to ensure that their clients get the most recent, relevant, actionable and valuable information for strategy development and to extract tangible results.

Read the rest here:

North America Biosimilars Market is projected to grow at CAGR of 25.1% by 2030 The Greater Binghamton Business Journal - The Greater Binghamton...